Clinical Evaluation of Beta-Blockers in Various Forms of Angina Pectoris

  • Nina Rehnqvist
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 158)

Abstract

Beta-receptor blockers have been used in ischemic heart disease, especially in angina pectoris, since the late 1960s. Their evaluation has considered clinical findings, including symptoms, ischemic endpoints (such as myocardial infarction), and the need for revascularization, as well as investigative measures, such as signs of ischemia at exercise testing and during long-term ECG recording. It has been clearly shown that beta-blockers have beneficial effects on anginal symptoms and the signs of myocardial ischemia. However, whether there really is a primary preventive effect in patients with stable angina (as has been shown for post-MI patients) has not been studied. This chapter discusses the various mechanisms behind the beneficial effects of betablockers that may also influence prognosis, as well as some methodological problems related to clinical trials with beta-blockers.

Keywords

Cholesterol Fatigue Ischemia Pyridine Prostaglandin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Braunwald E. On the difference between the heart’s output and its contractile state. Circulation 1971;43:171–177.PubMedCrossRefGoogle Scholar
  2. 2.
    Downey HF, Bashour FA, Mandel T, Kechejian SJ, Underwood RH. Effects of isoproterenol on collateral blood flow in ischemic myocardium. Annual Meeting of the Midwest Section of the American Federation for Clinical Research, 1973.Google Scholar
  3. 3.
    Fox K, Jonathan A, Selwin A. Combined high dosage administration of nifedipine and propranolol in patients with angina pectoris. Clin Sci 1980;58:11–12.Google Scholar
  4. 4.
    Bevilacqua M, Savonitto S, Bosisio E, et al. Role of the Frank-Starling mechanism in maintaining cardiac output during increasing levels of treadmill exercise in beta-blocked normal men. Am J Cardiol 1989;63:853–857.PubMedCrossRefGoogle Scholar
  5. 5.
    Hamer J, Grandjean T, Melendey L, Sowton GE. Effect of propranolol (Inderal) in angina pectoris: Preliminary report. Br Med J 1964;2:720–723.PubMedCrossRefGoogle Scholar
  6. 6.
    Hjemdal P, Linde B. Adrenergic control of blood flow and lipolysis in human adipose tissue. In: H Refsum, OD Mjoes, eds. Alpha-Adrenoceptor Blockers in Cardiovascular Disease. Churchill Livingstone 1985:151–164.Google Scholar
  7. 7.
    Clausen T. Adrenergic control of Na+-K+ home-ostasis. Acta Med Scand 1983,(Suppl 672):111–115.Google Scholar
  8. 8.
    Kerry R, Scrutton MC. Platelet adrenoceptors. In: GL Longenecker, ed. The Platelet: Physiology and Pharmacology. Academic Press, 1985:113–157.Google Scholar
  9. 9.
    Winter K. The effect of betablockade on platelet function and fibrinolytic activity. J Cardiovasc Pharmacol 1987;10(Suppl 2):94–98.Google Scholar
  10. 10.
    Tannous R. Betablockers and the neutrophil. J Lab Clin Med 1987;109:109–110.PubMedGoogle Scholar
  11. 11.
    Strawn WB, Bondjers G, Kaplan JR, et al. Endothelial dysfunction in response to psychosocial stress in monkeys. Circulation Res 1991;68:1270–1279.PubMedCrossRefGoogle Scholar
  12. 12.
    Mueller HS, Ayres SM Religa A, Evans RG. Propranolol in the treatment of acute myocardial infarction. Circulation 1974;49:1078–1087.PubMedCrossRefGoogle Scholar
  13. 13.
    ISIS I. Randomised trial of intravenous atenolol among 16,027 cases of suspected myocardial infarction. Lancet 1986;2:57–66.Google Scholar
  14. 14.
    Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Betablockade during and after myocardial infarction. An overview of the randomised trials. Prog Cardiovasc Dis 1985;27:335–371.PubMedCrossRefGoogle Scholar
  15. 15.
    Wit AL, Hoffman BF, Rosen MR. Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiology effects of beta-adrenergic receptor stimulation and blockade Part B. Am Heart J 1975;90:665–675.PubMedCrossRefGoogle Scholar
  16. 16.
    Olsson G, Rehnqvist N. Ventricular arrhythmias during the first year after myocardial infarction. Influence of long-term treatment with metoprolol. Circulation 1984;69:1129–1134.PubMedCrossRefGoogle Scholar
  17. 17.
    Thadani U, Davidson C, Singleton W, Taylor SH. Comparison of five beta-adrenoceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med 1980;68:243–250.PubMedCrossRefGoogle Scholar
  18. 18.
    Polese A, De Cesare N, Loaldi A, Lundgren B, Savonitto S. Cardioselective beta-blockade with metoprolol in rest angina: A randomized, double-blind, placebo-controlled, cross-over trial. Cardiologia 1989;34:333–339.PubMedGoogle Scholar
  19. 19.
    Ardissino D, Savonitto S, Egstrup K, et al. Transient myocardial ischemia during daily life in rest and exertional angina pectoris and comparison of effectiveness of metoprolol versus nifedipine. Am J Cardiol 1991;67.946–952.PubMedCrossRefGoogle Scholar
  20. 20.
    Ardissino D, Savonitto S, Egstrup K, et al. Selection of medical treatment for stable angina pectoris. Result of the International Multicenter AnGina Exercise Study (IMAGE), in press.Google Scholar
  21. 21.
    Besterman E. Nocturnal angina. Lancet 1972;1:1067.PubMedCrossRefGoogle Scholar
  22. 22.
    Robertson RM, Wood AJ, Vaugh WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982;65:281–285.PubMedCrossRefGoogle Scholar
  23. 23.
    Maseri A, Seven S, De Nes M, et al. Variant angina: One aspect of a continuous spectrum of vasospastic myocardial ischemia. Am J Cardiol 1978;42:1019–1035.PubMedCrossRefGoogle Scholar
  24. 24.
    Ardissino D, De Servi S, Barberis P, et al. Significance of hyperventilation-induced ST segment depression in patients with coronary artery disease J Am Coll Cardiol 1989,13:804–810.PubMedCrossRefGoogle Scholar
  25. 25.
    Frishman WH, Christodoulou J, Weksler B, Smithen C, Killip T, Scheldt S. Abrupt propranolol withdrawal in angina pectoris: Effects on platelet aggregation and exercise tolerance. Am Heart J 1978;95:169–179PubMedCrossRefGoogle Scholar
  26. 26.
    Mehta J, Mehta P. Effects of propranolol therapy on platelet release and prostaglandin generation in patients with coronary artery disease. Circulation 1982;66:1294–1299.PubMedCrossRefGoogle Scholar
  27. 27.
    Day JL, Simpson N, Metcalfe J, Page RL. Metabolic consequences of atenolol and propranolol in the treatment of essential hypertension. Br Med J 1979,1:77–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Chobanian AV, Bracker P, Chan C. Effects of propranolol on atherogenesis in the cholesterol fed rabbit. Circ Res 1985,56:755–762.PubMedCrossRefGoogle Scholar
  29. 29.
    Lundin P, Eriksson SV, Erhardt L, Strandberg LE, Rehnqvist N. Continuous vector cardiography in patients with chest pain suggestive of acute ischemic heart disease. Cardiology, in press.Google Scholar
  30. 30.
    Julian DG. Comparisons and combinations in antianginal therapy Eur Heart J 1985;6:37–45.PubMedCrossRefGoogle Scholar
  31. 31.
    Juul-Moeller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992,340:1421–1425.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Nina Rehnqvist

There are no affiliations available

Personalised recommendations